KRAS and gastric cancer: Cetuximab has exhibited the potential for GC treatment, which functions by binding to the ubiquitous HER1(EGFR); based on success in treating colorectal cancer patients, cetuximab is currently one of the promising new candidates for treatment of gastric cancer due to its very low mutation rate of K-RAS.